Scarica l'app Stockscreener
33.43
2.92%
0.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq
Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire
Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Supernus: Q1 Earnings Snapshot - CTPost
Earnings call transcript: Supernus Q1 2025 earnings miss expectations - Investing.com
Supernus Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Est - GuruFocus
SUPN Reports Higher than Expected Q1 Revenue at $149.8M | SUPN S - GuruFocus
Supernus Announces First Quarter 2025 Financial Results | SUPN S - GuruFocus
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
SUPERNUS PHARMACEUTICALS Earnings Results: $SUPN Reports Quarterly Earnings - Nasdaq
Earnings Flash (SUPN) Supernus Pharmaceuticals Q1 Loss Per Share $0.21 Vs. FactSet Est. Loss $0.01 - marketscreener.com
Supernus Announces First Quarter 2025 Financial Results | SUPN Stock News - GuruFocus
Supernus Announces First Quarter 2025 Financial Results - GlobeNewswire
Investors who Lost Money on Supernus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationSUPN - ACCESS Newswire
Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview - Nasdaq
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - Louisiana First News
Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance
How To Trade (SUPN) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Supernus: New Direction Beckons After MDD Drug Fail (Rating Downgrade) (NASDAQ:SUPN) - Seeking Alpha
BlackRock, Inc. Reduces Stake in Supernus Pharmaceuticals Inc - GuruFocus
Supernus Pharmaceuticals (NASDAQ:SUPN) investors are up 6.5% in the past week, but earnings have declined over the last five years - simplywall.st
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals - The Globe and Mail
What Makes Supernus (SUPN) a New Buy Stock - Yahoo Finance
Investor Network: Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Envestnet Asset Management Inc. Has $2.17 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
LPL Financial LLC Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Bank of Montreal Can Buys 473 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):